Cancer is rising at an increasingly alarming pace. Early-onset malignancies are climbing in younger adults, aggressive cancers are appearing in patients with little warning, and U.S. cancer mortality has departed sharply from its pre-pandemic trajectory. Against this backdrop, one of the most important questions in medicine is whether the unprecedented mass deployment of nucleoside-modified mRNA technology could be contributing to cancer initiation, reactivation, or accelerated progression.
We have now fully answered this question in a new paper titled “Potential Oncogenicity of Synthetic mRNA Vaccines: Convergent Mechanistic, Clinical, and Population Evidence for a Concurrent-Hit Model of Accelerated Malignancy” authored by John A. Catanzaro, NMD, PhD; Nicolas Hulscher, MPH (myself); Raphael B. Stricker, MD; Jamie K. Waselenko, MD, FACP, FICT; and Peter A. McCullough, MD, MPH.
In the most comprehensive analysis to date examining the link between mRNA “vaccines” and cancer, we brought together mechanistic biology, published clinical cases, large population cohorts, U.S. cancer-incidence data, and national mortality records to evaluate whether these gene products could induce, accelerate, or unmask malignancy.
The findings converge on the same alarming picture: TURBO CANCER IS REAL.
And the implications extend far beyond COVID-19 vaccination, because the same underlying mRNA technology is now being pushed directly into cancer treatment.
Below is a concise breakdown of what we found: